{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:01:23Z","timestamp":1788940883789,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose \n<\/jats:title>\n                <jats:p>The curative strategy for patients with esophageal cancer without distant metastases consists of esophagectomy with preceding chemo(radio)therapy (CRT). In 10\u201340% of patients treated with CRT, no viable tumor is detectable in the resection specimen (pathological complete response (pCR)). This study aims to define the clinical outcomes of patients with a pCR and to assess the accuracy of post-CRT FDG-PET\/CT in the detection of a pCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four hundred sixty-three patients with cancer of the esophagus or gastroesophageal junction who underwent esophageal resection after CRT between 1994 and 2013 were included. Patients were categorized as pathological complete responders or noncomplete responders. Standardized uptake value (SUV) ratios of 135 post-CRT FDG-PET\/CTs were calculated and compared with the pathological findings in the corresponding resection specimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 463 included patients, 85 (18.4%) patients had a pCR. During follow-up, 25 (29.4%) of these 85 patients developed recurrent disease. Both 5-year disease-free survival (5y-DFS) and 5-year overall survival (5y-OS) were significantly higher in complete responders compared to noncomplete responders (5y-DFS 69.6% vs. 44.2%; <jats:italic>P<\/jats:italic>\u2009=\u20090.001 and 5y-OS 66.5% vs. 43.7%; <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Not pCR, but only pN0 was identified as an independent predictor of (disease-free) survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with a pCR have a higher probability of survival compared to noncomplete responders. One third of patients with a pCR do develop recurrent disease, and pCR can therefore not be equated with cure. FDG<jats:bold>-<\/jats:bold>PET\/CT was inaccurate to predict pCR and therefore cannot be used as a sole diagnostic tool to predict pCR after CRT for esophageal cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12029-023-00951-2","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T22:01:39Z","timestamp":1688248899000},"page":"270-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["18F-FDG-PET\/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction: Accuracy and Long-Term Implications"],"prefix":"10.1007","volume":"55","author":[{"given":"D. C.","family":"van der Aa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Gisbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. J.","family":"Anderegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"van Dieren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MCCM","family":"Hulshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJGHM","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Bennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"van Berge Henegouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"951_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK. Jobe B a, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400\u201312.","journal-title":"Lancet"},{"key":"951_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"951_CR3","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"951_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"951_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/fon.09.133","volume":"6","author":"E Bollschweiler","year":"2010","unstructured":"Bollschweiler E, H\u00f6lscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol. 2010;6:25\u201335.","journal-title":"Future Oncol"},{"key":"951_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138.","journal-title":"Lancet Oncol"},{"key":"951_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681\u201392.","journal-title":"Lancet Oncol"},{"key":"951_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/bjs.8968","volume":"100","author":"P van Hagen","year":"2013","unstructured":"van Hagen P, Wijnhoven BPL, Nafteux P, et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2013;100:267\u201373.","journal-title":"Br J Surg"},{"key":"951_CR9","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/annonc\/mdt141","volume":"24","author":"S Lorenzen","year":"2013","unstructured":"Lorenzen S, Thuss-Patience P, Al-Batran SE, et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013;24:2068\u201373.","journal-title":"Ann Oncol"},{"key":"951_CR10","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1200\/JCO.2005.05.017","volume":"23","author":"AC Berger","year":"2005","unstructured":"Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330\u20137.","journal-title":"J Clin Oncol"},{"key":"951_CR11","doi-asserted-by":"crossref","unstructured":"Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376\u201384; discussion 384\u20135.","DOI":"10.1097\/00000658-200209000-00014"},{"key":"951_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/SLA.0b013e3181fb8dde","volume":"252","author":"D Vallb\u00f6hmer","year":"2010","unstructured":"Vallb\u00f6hmer D, H\u00f6lscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy\/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744\u20139.","journal-title":"Ann Surg"},{"key":"951_CR13","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062\u20137.","journal-title":"J Clin Oncol"},{"key":"951_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.bjc.6604200","volume":"98","author":"EPM van Vliet","year":"2008","unstructured":"van Vliet EPM, Heijenbrok-Kal MH, Hunink MGM, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547\u201357.","journal-title":"Br J Cancer"},{"key":"951_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.crad.2008.05.010","volume":"63","author":"FU Chowdhury","year":"2008","unstructured":"Chowdhury FU, Bradley KM, Gleeson FV. The role of 18F-FDG PET\/CT in the evaluation of oesophageal carcinoma. Clin Radiol. 2008;63:1297\u2013309.","journal-title":"Clin Radiol"},{"key":"951_CR16","first-page":"1118","volume":"46","author":"L Cong","year":"2016","unstructured":"Cong L, Wang S, Gao T, Hu L. The predictive value of 18 F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis. Jpn J Clin Oncol. 2016;46:1118\u201326.","journal-title":"Jpn J Clin Oncol"},{"key":"951_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2214\/AJR.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. Am J Roentgenol. 2010;195:310\u201320.","journal-title":"Am J Roentgenol"},{"key":"951_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/02656730802464078","volume":"25","author":"MCCM Hulshof","year":"2009","unstructured":"Hulshof MCCM, Van Haaren PMA, Van Lanschot JJB, et al. Preoperative chemoradiation combined with regional hyperthermia for patients with resectable esophageal cancer. Int J Hyperth. 2009;25:79\u201385.","journal-title":"Int J Hyperth"},{"key":"951_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijrobp.2014.05.022","volume":"90","author":"S Kordes","year":"2014","unstructured":"Kordes S, van Berge Henegouwen MI, Hulshof MC, et al. Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study. Int J Radiat Oncol. 2014;90:190\u20136.","journal-title":"Int J Radiat Oncol"},{"key":"951_CR20","doi-asserted-by":"crossref","unstructured":"Biere SS a Y, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379:1887\u201392.","DOI":"10.1016\/S0140-6736(12)60516-9"},{"key":"951_CR21","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/NEJMoa022343","volume":"347","author":"JBF Hulscher","year":"2002","unstructured":"Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662\u20139.","journal-title":"N Engl J Med"},{"key":"951_CR22","doi-asserted-by":"crossref","unstructured":"Mandard a M, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680\u20136.","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"key":"951_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2005.03.3688","volume":"24","author":"R Luthra","year":"2006","unstructured":"Luthra R, Wu T-T, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259\u201367.","journal-title":"J Clin Oncol"},{"key":"951_CR24","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00259-007-0521-3","volume":"34","author":"HA Wieder","year":"2007","unstructured":"Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"951_CR25","doi-asserted-by":"crossref","unstructured":"Ajani J a, Correa a M, Hofstetter WL, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012;23:2638\u201342.","DOI":"10.1093\/annonc\/mds210"},{"key":"951_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/SLA.0000000000001902","volume":"264","author":"HM Heneghan","year":"2016","unstructured":"Heneghan HM, Donohoe C, Elliot J, et al. Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer? Ann Surg. 2016;264:831\u20138.","journal-title":"Ann Surg"},{"key":"951_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/hep.26781","volume":"59","author":"M Bieze","year":"2014","unstructured":"Bieze M, Kl\u00fcmpen H-J, Verheij J, et al. Diagnostic accuracy of 18 F-methylcholine positron emission tomography\/computed tomography for intra- and extrahepatic hepatocellular carcinoma. Hepatology. 2014;59:996\u20131006.","journal-title":"Hepatology"},{"key":"951_CR28","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.4320","volume":"4","author":"BJ Noordman","year":"2015","unstructured":"Noordman BJ, Shapiro J, Spaander MC, et al. Accuracy of detecting residual disease after cross neoadjuvant chemoradiotherapy for esophageal cancer (preSANO Trial): rationale and protocol. JMIR Res Protoc. 2015;4: e79.","journal-title":"JMIR Res Protoc"},{"key":"951_CR29","doi-asserted-by":"crossref","unstructured":"Omloo JMT, Lagarde SM, Hulscher JBF, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid\/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992\u20131000; discussion 1000\u20131.","DOI":"10.1097\/SLA.0b013e31815c4037"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00951-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-023-00951-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00951-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:33:18Z","timestamp":1715761998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-023-00951-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s12029-023-00951-2","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"9 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Bergman is a consultant for Boston Scientific, Cook Medical, and Medtronic and has received research funding from Aqua Medical, Fuji Film, Olympus Endoscopy, Pentax Medical, and Medtronic. Van Laarhoven has served as a consultant for BMS, Celgene, Lilly, and Nordic and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, Roche, and Servier. Van Berge Henegouwen reports research grants from Stryker, in addition to consulting fees from Medtronic, Mylan BBraun, and Johnson and Johnson. The remaining authors have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of Interests"}}]}}